SCHEMBL5335902

SCHEMBL5335902

CCCc1ccc(S(=O)(=O)Nc2ccc(OC)nc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
PABPC1 P11940 2/20 0.57
HTT P42858 4/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPC1 O15118 1/20 0.55
MAPT P10636 4/20 0.53
ALDH1A1 P00352 3/20 0.53
LMNA P02545 3/20 0.53
ALOX15 P16050 2/20 0.53
USP2 O75604 2/20 0.53
TSHR P16473 2/20 0.53
HPGD P15428 1/20 0.53
TP53 P04637 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
FFAR4 Q5NUL3 2/20 0.52
FFAR1 O14842 1/20 0.52
KDM4E B2RXH2 1/20 0.52
POLB P06746 1/20 0.52
ATM Q13315 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24980451 0.81 MEN1 (0.65) MEN1KMT2APABPC1HTTSMN1; SMN2
SCHEMBL20715880 0.80 PKM (0.67) MEN1KMT2AHTTSMN1; SMN2MAPT
SCHEMBL1037705 0.79 MEN1 (0.59) MEN1KMT2APABPC1HTTSMN1; SMN2
SCHEMBL19303544 0.76 TSHR (0.63) MEN1KMT2APABPC1HTTSMN1; SMN2
SCHEMBL5349477 0.76 CYP2C19 (0.48) MEN1KMT2AHTTSMN1; SMN2MAPT
SCHEMBL31681202 0.75 ATM (0.63) MEN1KMT2AHTTMAPTALDH1A1
SCHEMBL31681351 0.75 FFAR4 (0.81) MAPTLMNAHPGDTP53FFAR4
SCHEMBL31681387 0.75 FFAR4 (0.62) MEN1KMT2AHTTMAPTALDH1A1
SCHEMBL31681421 0.75 FFAR4 (0.62) MEN1KMT2AHTTMAPTALDH1A1
SCHEMBL1038586 0.74 MEN1 (0.65) MEN1KMT2APABPC1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7230020-B2 11β-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2007-06-12 US disclosed
US-7230020-B2 11β-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2007-06-12 US disclosed
US-7230020-B2 11β-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2007-06-12 US disclosed
EP-1675844-A1 PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE Sterix Limited (GB) 2006-07-05 EP disclosed
US-20050227987-A1 11beta-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2005-10-13 US disclosed
WO-2005042513-A1 PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE STERIX LIMITED (GB) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227987-A1 11beta-hydroxysteroid dehydrogenase inhibitors HSD3B1, HSD3B2, HSD17B3 MEN1 2978/4885KMT2A 1973/4885PABPC1 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.